Rheumatology Advance Access published online on May 18, 2005
Rheumatology, doi:10.1093/rheumatology/keh688
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Charité University Hospital, Rheumatology and Clinical Immunology, Berlin, Germany
* To whom correspondence should be addressed.
Received March 22, 2005
Accepted April 15, 2005
6th European Lupus Meeting
Key autoantigens in SLE
2 University of California Los Angeles, Rheumatology, Los Angeles, California, USA
G. Riemekasten, E-mail: gabriela.riemekasten{at}charite.de
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
A. Sharabi, D. Luger, H. Ben-David, M. Dayan, H. Zinger, and E. Mozes The Role of Apoptosis in the Ameliorating Effects of a CDR1-Based Peptide on Lupus Manifestations in a Mouse Model J. Immunol., October 15, 2007; 179(8): 4979 - 4987. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Ishii, Y Muramoto, H Kosaka, S Ohshima, T Mima, Y Katada, S Hirohata, and Y Saeki A serological switching from anti-dsDNA to anti-Sm antibodies coincided with severe clinical manifestations of systemic lupus erythematosus (hemophagocytosis, profundus and psychosis) Lupus, January 1, 2007; 16(1): 67 - 69. [PDF] |
||||

